Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone plus nintedanib safety study in idiopathic pulmonary fibrosis
2015-003280-11Phase 4Completed
- Sponsor
- Roche
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pirfenidone and nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Roche. Primary endpoint: Proportion of patients completing 24 weeks of combination treatment. Started Oct 2015; status: completed.
02
Drugs
pirfenidonenintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2015-003280-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003280-11.